A detailed research comparison of GLP-3 and GLP-1 examining triple receptor agonism versus single GLP-1 receptor agonism, binding profiles, key mechanistic differences, and laboratory applications.
Part of the PeptidesATX Research Hub
Glucagon-like peptide-1 (GLP-1) receptor agonists have become a major area of focus in metabolic research. These peptides mimic or enhance the activity of endogenous incretin hormones, which play key roles in glucose homeostasis, insulin signaling, and energy balance. Over the past decade, the research landscape has expanded from single-receptor agonists like GLP-1 to multi-receptor agonists such as GLP-3, which engage two or three incretin-related receptors simultaneously.
This evolution reflects a growing understanding that metabolic regulation involves interconnected receptor systems. By comparing GLP-3 and GLP-1, researchers can examine how single versus triple receptor agonism influences metabolic parameters in preclinical models. This article provides a research-focused comparison of these two compounds, covering their structures, mechanisms, receptor binding profiles, and laboratory applications. All information presented is for educational and research reference purposes only.
GLP-1 is a modified GLP-1 analog with a molecular structure engineered for extended activity. It is based on the native GLP-1(7-37) sequence with key modifications: an amino acid substitution at position 8 (Aib, alpha-aminoisobutyric acid) that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, and a C-18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to albumin.
GLP-1 exerts its effects exclusively through the GLP-1 receptor, a G-protein coupled receptor (GPCR) expressed in pancreatic beta cells, the gastrointestinal tract, and the central nervous system. Upon binding, it activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. This signaling cascade is associated with glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and modulation of appetite-related neural pathways in research models.
As a single agonist, GLP-1 demonstrates high selectivity for the GLP-1 receptor with minimal cross-reactivity at GIP or glucagon receptors. This selectivity means its research effects are channeled through one receptor pathway, making it a well-characterized tool for studying GLP-1-specific signaling in isolation. For a comprehensive overview, see our GLP-1 research peptide guide.
GLP-3 (also referenced as LY3437943) is a single-molecule triple agonist that simultaneously engages three distinct receptors: the GLP-1 receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This tri-agonist design represents a significant advancement in peptide engineering, combining three receptor-targeting activities into one compound.
GLP-3 is a single synthetic peptide engineered to activate all three receptors, carrying a fatty-acid acylation intended to promote albumin binding and extend its circulating half-life. In vitro it shows balanced glucagon-receptor and GLP-1-receptor activity with greater GIP-receptor activity (Coskun et al., Cell Metab 2022). Its residue count and acyl chain are not stated here because they were not verified from an accessible primary source.
The triple agonist mechanism of GLP-3 engages three complementary metabolic pathways in preclinical research models:
The inclusion of glucagon receptor agonism is a distinguishing feature. While glucagon is traditionally associated with elevating blood glucose, controlled glucagon receptor activation in the context of concurrent GLP-1 and GIP signaling has been observed to influence energy expenditure and lipid metabolism in animal models. For a detailed overview, refer to our GLP-3 research peptide guide.
Understanding the receptor binding profiles of these two compounds is fundamental to interpreting their differing research applications:
| Property | GLP-1 | GLP-3 |
|---|---|---|
| GLP-1 Receptor | Agonist (its only target) | Agonist — activity balanced with its glucagon-receptor activity in vitro (Coskun 2022) |
| GIP Receptor | No significant activity | Agonist — greater activity than at the GLP-1 and glucagon receptors in vitro (Coskun 2022) |
| Glucagon Receptor | No significant activity | Agonist — balanced with GLP-1-receptor activity in vitro (Coskun 2022) |
| Receptor Classification | Single agonist (mono-agonist) | Triple agonist (tri-agonist) |
| Signaling Pathways | cAMP via GLP-1R only | cAMP via GLP-1R, GIPR, and GCGR |
| Structural Basis | Modified GLP-1 analog | Engineered tri-agonist peptide |
This comparison illustrates how GLP-3's design broadens the scope of receptor engagement relative to GLP-1.
The most significant mechanistic distinction between these compounds is the number of receptor systems engaged. GLP-1's single agonism provides a well-defined, predictable pharmacological profile. GLP-3's triple agonism introduces additional variables, as the three receptor systems interact; in obese mice, glucagon-receptor-driven energy expenditure added to the calorie-intake reduction driven by the two incretin receptors (Coskun et al., Cell Metab 2022).
In preclinical models, this difference has been observed in the magnitude and breadth of metabolic responses. While GLP-1 research focuses on GLP-1-mediated effects, GLP-3 research explores how the addition of GIP and glucagon receptor signaling modifies or amplifies those effects.
The metabolic pathways engaged by each compound reflect their receptor profiles:
These mechanistic differences make the two compounds complementary research tools. Researchers may also find value in comparing these compounds alongside dual agonists such as GLP-2, which targets GLP-1 and GIP receptors.
Both GLP-1 and GLP-3 are utilized in metabolic research to investigate incretin receptor signaling, though their distinct receptor profiles make them suitable for different research questions.
In preclinical weight management models, both compounds have been studied for their effects on body weight parameters. GLP-1 research has generated a substantial body of literature on GLP-1-mediated appetite and body composition changes. GLP-3 research has explored whether the addition of GIP and glucagon receptor agonism produces differential effects on body weight, fat mass distribution, and energy expenditure in animal models.
Glucose homeostasis research benefits from having both single and triple agonists available for comparative studies. Proper handling of these compounds is essential for reproducible results. Both should be reconstituted using bacteriostatic water under aseptic laboratory conditions.
Understanding the pharmacokinetic differences between GLP-3 and GLP-1 is important for designing research protocols:
For both compounds, researchers should consult the Certificate of Analysis for batch-specific data on purity, identity, and recommended handling conditions. For detailed sourcing criteria specific to the triple agonist compound, see the research-grade GLP-3 product page and its lot certificate.
The research landscape for these two compounds differs in maturity and scope:
Researchers may also benefit from examining our GLP-3 vs GLP-2 comparison for additional context on multi-receptor agonist research.
Sources: Lau J, et al. J Med Chem. 2015;58(18):7370–7380 (GLP-1 analogue design — Aib8, Arg34, acylation at Lys26 — and mini-pig pharmacokinetics; PubMed 26308095). Coskun T, et al. Cell Metab. 2022;34(9):1234–1247 (GLP-3 in vitro receptor profile and obese-mouse studies; PubMed 35985340). Urva S, et al. Lancet. 2022;400(10366):1869–1881 (human phase 1b pharmacokinetics — context only; PubMed 36354040). Jastreboff AM, et al. N Engl J Med. 2023;389(6):514–526 (human phase 2 — clinical development status only). GLP-1 half-life and acylation: FDA prescribing information for the approved product (DailyMed).
Browse our full catalog of research-grade peptides, including GLP-3 and other GLP-1 based compounds, in our research peptide shop.
The primary difference lies in receptor selectivity. GLP-1 is a single GLP-1 receptor agonist, while GLP-3 is a triple agonist that targets GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This triple agonism enables GLP-3 to engage multiple metabolic pathways in preclinical research models.
GLP-1 binds exclusively to the GLP-1 receptor with high affinity. GLP-3 binds to three distinct receptors: GLP-1, GIP, and glucagon receptors. The GIP receptor component is the primary agonist in GLP-3's design, with GLP-1 and glucagon receptor activity contributing complementary metabolic signaling in research settings.
GLP-1 has received regulatory approvals for specific therapeutic indications under various brand names. GLP-3 remains an investigational compound currently undergoing clinical trials and is not approved for human therapeutic use. Both compounds sold by research peptide suppliers are intended strictly for laboratory research purposes only.
In preclinical research, GLP-3's triple agonism engages three complementary metabolic pathways: GLP-1 receptor activation influences insulin secretion and appetite signaling, GIP receptor activation modulates incretin-related metabolic processes, and glucagon receptor activation affects hepatic glucose output and energy expenditure. These combined pathways are studied together for their effects on metabolic parameters in laboratory models.
Both GLP-3 and GLP-1 in lyophilized form should be stored at -20°C or below, protected from light and moisture. Reconstitution should be performed using bacteriostatic water under aseptic conditions. Once reconstituted, store at 2-8°C and minimize freeze-thaw cycles. See our complete peptide reconstitution guide for step-by-step instructions.
Access quality documentation and research-grade compounds for your laboratory investigations.
View Certificates of Analysis Explore Research-Grade PeptidesDisclaimer: These compounds are intended for laboratory research use only. They are not approved for human or veterinary use. The information presented in this article is for educational and research reference purposes and does not constitute medical advice or therapeutic recommendations.